FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Glenmark Pharmaceuticals Pravastatin Sodium Tablets Recall

Pravastatin Sodium Tablets, USP 80mg, packaged in a) 90-count bottle

Glenmark Pharmaceuticals Inc., USA · Mahwah, NJ

Risk level
Class II
Reported by FDA
Jul 24, 2024
Recall ID
D-0612-2024
Check your lot numberHow we source this data

Summary

Glenmark Pharmaceuticals recalled Pravastatin Sodium Tablets starting Jun 28, 2024. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0612-2024 on Jul 24, 2024. Reason: Failed Dissolution Specifications: results below specifications. Status: Ongoing.

Why it was recalled

Failed Dissolution Specifications: results below specifications

Product description

Pravastatin Sodium Tablets, USP 80mg, packaged in a) 90-count bottle, NDC 68462-198-90; b) 500-count bottle, NDC 68462-198-05, Rx only, Manufactured by: Glenmark Pharmaceuticals Limited Pithampur, Madhya Pradesh 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430,

Lot numbers, UPCs & expiration codes

Lot#: a) 17211249, 17211264, 17211266,17211286, Exp 6/30/24; 17211525, 17211535, 17211549, Exp 7/31/24; 17211787, 17211801, 8/31/24; 17212041, 9/30/24; 17212088, 17212106, Exp 10/31/24; 17212346, 17212345, 11/30/24; 17220053, 17220054, 17220055 12/31/24; 17220309, 17220310, Exp 1/31/25; b) 17211290, 6/30/2024

Where it was sold

USA Nationwide

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0612-2024
Classification
Class II
Status
Ongoing
Recall initiated
Jun 28, 2024
FDA report date
Jul 24, 2024
Quantity
a) 145,800 bottles; b) 1,368 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Glenmark Pharmaceuticals Inc., USA

Original FDA data

Every field from FDA enforcement report D-0612-2024, exactly as published.

Show all FDA fields
City
Mahwah
State
NJ
Status
Ongoing
Country
United States
Event ID
94899
Address
750 Corporate Dr
Code information
Lot#: a) 17211249, 17211264, 17211266,17211286, Exp 6/30/24; 17211525, 17211535, 17211549, Exp 7/31/24; 17211787, 17211801, 8/31/24; 17212041, 9/30/24; 17212088, 17212106, Exp 10/31/24; 17212346, 17212345, 11/30/24; 17220053, 17220054, 17220055 12/31/24; 17220309, 17220310, Exp 1/31/25; b) 17211290, 6/30/2024
Postal code
07430-2009
Report date
Jul 24, 2024
Product type
Drugs
Recall number
D-0612-2024
Classification
Class II
Recalling firm
Glenmark Pharmaceuticals Inc., USA
Product quantity
a) 145,800 bottles; b) 1,368 bottles
Reason for recall
Failed Dissolution Specifications: results below specifications
Voluntary / mandated
Voluntary: Firm initiated
Product description
Pravastatin Sodium Tablets, USP 80mg, packaged in a) 90-count bottle, NDC 68462-198-90; b) 500-count bottle, NDC 68462-198-05, Rx only, Manufactured by: Glenmark Pharmaceuticals Limited Pithampur, Madhya Pradesh 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430,
Distribution pattern
USA Nationwide
Recall initiation date
Jun 28, 2024
Center classification date
Jul 18, 2024

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0612-2024, published Jul 24, 2024. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls